Treatment Selection Choices Should Not Be Based on Benefits or Costs Alone: A Head-to-Head Randomized Controlled Trial of Antiviral Drugs for Hepatitis C
Table 3
SVR24 rates based on treatment exposure to boceprevir and telaprevir.
Click through the PLOS taxonomy to find articles in your field.
For more information about PLOS Subject Areas, click here.
SVR24 rates based on treatment exposure to boceprevir and telaprevir.
Our website uses different types of cookies. Optional cookies will only be set with your consent and you may withdraw this consent at any time. Below you can learn more about the types of cookies PLOS uses and register your cookie preferences.